FDA Approves First-in-Class Non-Opioid Pain Reliever
Journavx (suzetrigine) – a first-in-class, non-opioid analgesicA new non-opioid pain treatment option
On January 30, 2025, the FDA granted priority review for Journavx (suzetrigine) – a first-in-class, non-opioid analgesic for treating moderate to severe acute pain in adults.
How It Works
Journavx targets sodium channels in the peripheral nervous system, interrupting pain signals before they reach the brain — offering a novel mechanism of action with no opioid involvement.
Key Trial Results
- Evaluated in two surgical pain studies (abdominoplasty and bunionectomy).
- Patients using Journavx had significantly better pain relief than those on placebo.
- Common side effects: itching, muscle spasms, rash, and elevated creatine phosphokinase.
Warnings
Users should avoid grapefruit and strong CYP3A inhibitors due to interaction risk.
Why It Matters
This marks the first approval in a new class of non-opioid pain medicines, aligning with the FDA’s push to expand safer alternatives amid the opioid crisis.
Approved by: Vertex Pharmaceuticals
Designations: Breakthrough Therapy, Fast Track, Priority Review
Journavx offers a promising new option for acute pain relief — without the risks of opioids.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Approval for Cancer Treatment Aid
The Food and Drug Administration (FDA) on 12 December 2022 announced the approval of Agilent's Resolution CTDX FIRST, a new in vitro diagnostic (IVD) medical device for use in the detecting a specific mutation in the KRAS gene in circulating cell-free DNA. This test...
FDA Accelerated Approval for Alzheimer’s Disease Treatment
The US Food and Drug Administration (FDA) announced on 06 January, 2023 that it had granted accelerated approval for the Alzheimer's disease treatment Leqembi. This is a significant milestone in the fight against Alzheimer's, a debilitating and progressive brain...
FDA Issues Letter to Warn of Abbott Trifecta Valve Risks
Letter outlines risks associated with the heart valve On February 27, the FDA released a letter to healthcare providers concerning potential risks associated with Abbott Trifecta valves. The Trifecta valve is a type of heart valve that is implanted in patients during...